CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19,853,610 enrolled
Drug / intervention
Vaccinationbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06199934
NCT06199934N/ACompleted

Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

Pfizer·observational·Posted Jan 10, 2024·Updated Sep 10, 2025

In Brief

An observational study evaluating Vaccination for SARS-CoV-2 and COVID-19 Vaccines. Completed, enrolled 19,853,610 participants across 1 site.

Detailed Summary

The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. Pfizer is not enrolling any participants for this study. Instead, existing data from different health data sources will be used to help answer the scientific questions Pfizer is interested in learning more about.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedJan 10, 2024
Enrollment StartSep 11, 2023
Primary CompletionJul 31, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.5 years ago

Interventions

Vaccinationbiological

BNT162b2 vaccination